PolyPeptide Group Ltd
PPGN
ISIN CH1110760852 / Valor 111076085
PolyPeptide Group Ltd
UMushroom community rating:
About company
PolyPeptide Group Ltd is a Contract Development and Manufacturing Organization (CDMO) that specializes in the development and production of active pharmaceutical ingredients (APIs) for both proprietary and generic drugs. The company collaborates with pharmaceutical and biotechnology firms to support the creation and manufacturing processes of these essential components, which are critical in the formulation of various medications. With a focus on delivering high-quality APIs, PolyPeptide plays a significant role in the pharmaceutical supply chain, providing expertise and resources that enable its clients to bring their products to market efficiently and effectively.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (16.10.2025):
PolyPeptide Group Ltd reported its financial results for the full year 2024, demonstrating significant improvements in revenue, gross profit, and a reduction in net loss compared to the previous year.
Revenue Growth
Revenue increased to €336.8 million in 2024, up from €320.4 million in 2023, reflecting the company's expanding market presence and increased sales.
Improved Gross Profit
The gross profit surged to €39.3 million in 2024, a substantial rise from €9.1 million in 2023, indicating enhanced operational efficiency and cost management.
Reduction in Net Loss
Net loss attributable to shareholders decreased to €19.6 million in 2024, compared to €51.4 million in 2023, showcasing the company's progress towards financial stability.
Enhanced Earnings Per Share
Earnings per share improved to -€0.59 in 2024 from -€1.56 in 2023, reflecting the company's efforts to mitigate losses and improve shareholder value.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
998 M
Market cap (USD)
19,244
Daily traded volume (Shares)
29.45 / 28.75
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
